# Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02337478** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 5 (actual)

## Conditions studied

- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Vincristine Sulfate Liposome
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02337478
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-05
- **Primary completion:** 2016-03-31
- **Final completion:** 2017-09-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was stopped early due to futility.
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337478, "Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02337478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*